[BREAKING] Hemerion obtains the FDA clearance for its next US clinical trial


Hemerion at the Brain Tumor Symposium in Miami

The Hemerion technology presented at the Miami Global Brain Tumor Symposium

Pr. Nicolas Reyns, Head of the neurosurgery oncology dept. of the University Hospital of Lille, has been developing photodynamic therapy since 2010 in partnership with the Inserm laboratory U1189 OncoThAI.

He notably spearheaded ground-breaking glioblastoma treatments and co-invented the technology now developed by Hemerion.

Pr. Reyns has presented his experience developing photodynamic therapy for glioblastoma within the frame of the Miami Global Brain Tumor Symposium.

This presentation focused on the latest clinical outcomes obtained during the INDYGO clinical trial using the Hemerion technology, the upcoming milestones in the technological and the therapeutic developments of the technology.

The presentation was hosted by the Sylvester Comprehensive Cancer Center and the Department of Neurological Surgery at the University of Miami, Miller School of Medicine.